#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Congenital generalised lipodystrophy Lymphatic malformation Systemic scleroderma Antisynthetase syndrome Anti-myelin-associated glycoprotein associated polyneuropathy Urethral valves Kidney transplant rejection Medulloblastoma HER2 gene amplification Corneal neovascularisation Osteosarcoma recurrent Pancreatic carcinoma Extra-osseous Ewing's sarcoma recurrent B-cell small lymphocytic lymphoma recurrent Pemphigus More trials…

    Learn about Rare Diseases

    Methylmalonic acidaemia – Treatment Mucopolysaccharidosis III Lennox-Gastaut syndrome – Diagnostics Leiomyosarcoma metastatic – Diagnostics Systemic sclerosis pulmonary – Treatment Undifferentiated sarcoma – Trials in Disease Familial haemophagocytic lymphohistiocytosis – Trials in Disease CADASIL – Treatment Synovial sarcoma recurrent Alagille syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Gadoquatrane Gadoxetic Acid, Disodium Oxybuprocaine Human Serum Albumin Loperamide Reboxetine Mk-1167 Ribonucleic Acid K10 Pd01B Prednisone Acetate LUNSEKIMIG ULVIPRUBART Trastuzumab Emtansine ACETYLCARNITINE HYDROCHLORIDE Napabucasin Interleukin-2 Propylene Glycol Amisulpride Vinorelbine Tartrate Ro7589655 More therapies…

    Learn about Your Condition

    Bile duct adenocarcinoma Precocious puberty Pancreatic fistula Mumps Mantle cell lymphoma stage II Pancreatic carcinoma Partial seizures Factor VIII deficiency Dystonic tremor Osteomyelitis acute Post procedural oedema Squamous cell carcinoma Medulloblastoma recurrent Liver transplant Lung transplant rejection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. IRCCS Humanitas Research Hospital

IRCCS Humanitas Research Hospital

Via Alessandro Manzoni 56, Rozzano, 20089, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Long-Term Safety and Effects of Marstacimab for Patients with Severe Hemophilia A or B, With or Without Inhibitors

    Recruiting

    3 1 1
    Investigated Diseases:
    • Factor IX deficiency
    • Factor VIII deficiency
    Investigated Drugs:
    • Marstacimab
    Austria Croatia Czechia Denmark France Germany +3

  • Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Favezelimab
    • Lenvatinib
    • Olaparib
    Austria Belgium Czechia Denmark Estonia Finland +15

  • Study of ONC201 for Patients with Newly Diagnosed H3 K27M-mutant Diffuse Glioma After Radiotherapy

    Recruiting

    3 1
    Investigated Diseases:
    • Malignant glioma
    Investigated Drugs:
    • 2,4,6,7,8,9-Hexahydro-4-((2-Methylphenyl)Methyl)-7-(Phenylmethyl)Imidazo(1,2-A)Pyrido(3,4-E)Pyrimidin-5(1H)-One
    Austria Denmark Germany Italy The Netherlands Spain

  • Study on Marstacimab for Children with Severe Hemophilia A or B, With or Without Inhibitors

    Recruiting

    3 1 1
    Investigated Drugs:
    • Marstacimab
    Austria Czechia Denmark France Germany Italy +2

  • Study on Ivosidenib for Patients with Previously Treated Advanced or Metastatic Cholangiocarcinoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Ivosidenib
    Austria Belgium France Germany Ireland Italy +4

  • Study of Pre-Operative Treatments with Sotorasib and Drug Combination for Patients with Resectable Colorectal Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal adenocarcinoma
    Investigated Drugs:
    • 4-[1-[[6-[[4-(Trifluoromethyl)Phenyl]Methyl]-6-Azaspiro[2.5]Octane-7-Carbonyl]Amino]Cyclopropyl]Benzoic Acid
    • Balstilimab
    • Botensilimab
    Italy

  • Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency-Related Liver Disease and Fibrosis

    Recruiting

    3 1 1
    Investigated Drugs:
    • Fazirsiran
    • Saline
    Austria Belgium Czechia Denmark France Germany +7

  • Study on the Effectiveness of ADT with or without Darolutamide in Men with Newly Diagnosed Metastatic Prostate Cancer and Limited Functional Ability

    Recruiting

    3 1 1
    Investigated Drugs:
    • Darolutamide
    Belgium France Germany Ireland Italy The Netherlands +4

  • Study to Compare Fianlimab and Cemiplimab Combination with Pembrolizumab in Patients with High-Risk Melanoma After Surgery

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Fianlimab
    • Cemiplimab
    • Pembrolizumab
    Belgium Czechia France Germany Greece Ireland +4

  • Study on Cisplatin, Gemcitabine, and Paclitaxel Albumin-Bound for Patients with Resectable Biliary Tract Cancer at High Risk of Recurrence

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Biliary neoplasm
    Investigated Drugs:
    • Capecitabine
    • Cisplatin
    • Gemcitabine Hydrochloride
    Italy
Previous Page
1 … 26 27 28 29 30 … 69
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!